Whitehawk Therapeutics Reports Q2 2026 Financial Results

What Happened
Whitehawk Therapeutics, Inc. (WHWK) filed a Form 8-K on August 6, 2026 to announce its quarterly financial results for the quarter ended June 30, 2026. The company issued a press release reporting these quarterly results, which is attached to the 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• The 8-K was furnished on August 6, 2026 and covers the quarter ended June 30, 2026 (Q2 2026).
• The press release announcing the quarterly results is attached as Exhibit 99.1.
• The information furnished under Item 2.02 is expressly stated as “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.
• The exhibit is not deemed incorporated by reference into other filings under the Securities Act or the Exchange Act unless specifically referenced.

Why It Matters
This filing signals that Whitehawk has released its latest quarterly earnings and related financial information (earnings, revenue and other quarterly results) — key data investors use to assess company performance. Because the press release was furnished rather than filed, it is not subject to Section 18 liability and is not automatically incorporated into other SEC filings; investors should read the attached press release for the details and watch for subsequent SEC filings (e.g., Form 10-Q) for audited financial statements and fuller disclosure.